http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105315350-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105315350-B |
| titleOfInvention | Antiangiogenic polypeptide mPEG-Mal-Cys-AS16 |
| abstract | The invention belongs to biomedicine technical fields, and in particular to a kind of antiangiogenic polypeptide mPEG-Mal-Cys-AS16.The peptide includes 17 amino acid, specific amino acid sequence are as follows: mPEG-Mal-CATWLPPRAANLLMAAS.The present invention carries out chemical modification appropriate to AS16 by using polyethylene glycol, that is, can reach the purpose of extend it half-life period in vivo.Experiments have shown that, polypeptide mPEG-Mal-Cys-AS16 after ground provided by the present invention chemical modification, compared to original polypeptide AS16, its bioactivity has obtained preferable holding, but it can preferably avoid by the enzymatic hydrolysis of enzymes a variety of in organism or by glomerular filtration, its half-life period in vivo is preferably extended, thus there is preferably application value when being used for inhibiting tumour. |
| priorityDate | 2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.